Obtaining and screening compound collections: a user's guide and a call to chemists

Research output: Contribution to journalReview article

Abstract

Advances in genetics, proteomics and cell biology over the past 20 years have unearthed a multitude of potential macromolecular targets for the selective treatment of disease. The challenge remains to find appropriate small molecule ligands for these proteins (or nucleic acids), and to use these ligands to validate novel disease targets. The advent of low-cost instrumentation has made industrial-style high-throughput screening possible in academic settings. Unfortunately for many, access to large collections of compounds is still limited and limiting. This article is aimed at the user who has an interest in compound screening but does not have ready access to large collections of small molecules. High-throughput screening need not be the exclusive domain of institutions and centers with vast resources and NIH Roadmap-funded compound repositories. As it turns out, many of the most interesting compounds are probably within arm's reach, in our laboratory freezers and in those of our colleagues.

Original languageEnglish (US)
Pages (from-to)213-218
Number of pages6
JournalCurrent Opinion in Chemical Biology
Volume10
Issue number3
DOIs
StatePublished - Jun 1 2006

Fingerprint

Screening
Ligands
Throughput
Cytology
Proteomics
Nucleic Acids
Cell Biology
Molecules
Costs and Cost Analysis
Proteins
Costs
Therapeutics
Genetics

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry

Cite this

Obtaining and screening compound collections : a user's guide and a call to chemists. / Hergenrother, Paul.

In: Current Opinion in Chemical Biology, Vol. 10, No. 3, 01.06.2006, p. 213-218.

Research output: Contribution to journalReview article

@article{b4e6c4184f324e699b7b799b2b14d074,
title = "Obtaining and screening compound collections: a user's guide and a call to chemists",
abstract = "Advances in genetics, proteomics and cell biology over the past 20 years have unearthed a multitude of potential macromolecular targets for the selective treatment of disease. The challenge remains to find appropriate small molecule ligands for these proteins (or nucleic acids), and to use these ligands to validate novel disease targets. The advent of low-cost instrumentation has made industrial-style high-throughput screening possible in academic settings. Unfortunately for many, access to large collections of compounds is still limited and limiting. This article is aimed at the user who has an interest in compound screening but does not have ready access to large collections of small molecules. High-throughput screening need not be the exclusive domain of institutions and centers with vast resources and NIH Roadmap-funded compound repositories. As it turns out, many of the most interesting compounds are probably within arm's reach, in our laboratory freezers and in those of our colleagues.",
author = "Paul Hergenrother",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.cbpa.2006.04.005",
language = "English (US)",
volume = "10",
pages = "213--218",
journal = "Current Opinion in Chemical Biology",
issn = "1367-5931",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Obtaining and screening compound collections

T2 - a user's guide and a call to chemists

AU - Hergenrother, Paul

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Advances in genetics, proteomics and cell biology over the past 20 years have unearthed a multitude of potential macromolecular targets for the selective treatment of disease. The challenge remains to find appropriate small molecule ligands for these proteins (or nucleic acids), and to use these ligands to validate novel disease targets. The advent of low-cost instrumentation has made industrial-style high-throughput screening possible in academic settings. Unfortunately for many, access to large collections of compounds is still limited and limiting. This article is aimed at the user who has an interest in compound screening but does not have ready access to large collections of small molecules. High-throughput screening need not be the exclusive domain of institutions and centers with vast resources and NIH Roadmap-funded compound repositories. As it turns out, many of the most interesting compounds are probably within arm's reach, in our laboratory freezers and in those of our colleagues.

AB - Advances in genetics, proteomics and cell biology over the past 20 years have unearthed a multitude of potential macromolecular targets for the selective treatment of disease. The challenge remains to find appropriate small molecule ligands for these proteins (or nucleic acids), and to use these ligands to validate novel disease targets. The advent of low-cost instrumentation has made industrial-style high-throughput screening possible in academic settings. Unfortunately for many, access to large collections of compounds is still limited and limiting. This article is aimed at the user who has an interest in compound screening but does not have ready access to large collections of small molecules. High-throughput screening need not be the exclusive domain of institutions and centers with vast resources and NIH Roadmap-funded compound repositories. As it turns out, many of the most interesting compounds are probably within arm's reach, in our laboratory freezers and in those of our colleagues.

UR - http://www.scopus.com/inward/record.url?scp=33744521565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744521565&partnerID=8YFLogxK

U2 - 10.1016/j.cbpa.2006.04.005

DO - 10.1016/j.cbpa.2006.04.005

M3 - Review article

C2 - 16677847

AN - SCOPUS:33744521565

VL - 10

SP - 213

EP - 218

JO - Current Opinion in Chemical Biology

JF - Current Opinion in Chemical Biology

SN - 1367-5931

IS - 3

ER -